Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada
about
Overactive bladder: strategies to ensure treatment compliance and adherencePersistence and compliance with medication management in the treatment of overactive bladderCUA guideline on adult overactive bladderCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.The impact of persistence with mirabegron usage versus switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review.Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).Persistence with medication and overactive bladder: an ongoing challenge.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.Drug persistence and adherence in the treatment of overactive bladder.Drugs for the overactive bladder: are there differences in persistence and compliance?Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK.Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).Individualizing medical treatment of overactive bladderA retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
P2860
Q26746914-ADC2B0EC-06BB-4684-BAF5-8B88D2324242Q26765014-BCCFC243-1B96-4DDC-925C-E7D66D4146B2Q33665026-5FFAC66F-8B52-4C06-8E84-C73A1B4F815CQ33696642-85DCBE88-806B-42C5-84FE-D46A3AD18634Q33716568-64D5B17E-A5CF-44EA-83E1-571E71EE4135Q33727733-504C8EDC-1CBA-4089-8509-DD0E2AF78FDCQ37409521-484AF975-6B92-4F76-B038-29DDAE5876B1Q38612038-42AF7393-5EFC-47AE-A1D4-624C7C5C345FQ38626236-2B80F5CB-2ED2-4A30-BD9F-459952AE10DAQ38649685-02885648-80A3-4B98-AD61-5B093028CD53Q38668143-2E2015D5-A4D9-4488-A074-EEA632E818A2Q38832902-8A28AAD6-55A1-4132-9780-D7569DBC5238Q38870480-2CA605D7-D59B-4910-A3D4-90D9874CD4D5Q38911819-BAAB9411-30C2-4445-888A-F72862FF002BQ38950244-DEFF1D5C-8CC0-45BD-A829-A338B5A49513Q38990447-99C980DF-F6BF-4056-90B2-39E57C72669CQ39046374-21B16A74-759D-4A2D-A4A1-790FEA93C5F8Q39153362-5043F51B-988E-4C6B-9E2B-EC87FB99220EQ39667385-2DC243CC-2827-4389-99F0-BBBE960C1B98Q41931518-0729E71D-19B9-48DA-86BA-9017A764E0ADQ42332340-77BF67D7-D7B8-4168-B04C-9016474FF48DQ46638388-6413885D-8300-4BB6-BFBF-091D352F233FQ47563038-5A357A76-1E0E-4814-A075-ADBEA6C661FCQ48261630-D94864F2-48E1-4F07-8189-09FDD96C0B44Q48300325-9DA1D2B6-6674-4C73-BF28-47DAB05A2FE6Q48347597-4DBAF133-BA57-40A5-A246-4A5B16824D43Q50890665-FE46C576-003B-46FC-910C-94D96A1201FAQ55359372-7ED833A7-CE6B-46A6-AD9C-53D521C64ED0Q57298524-EDD1E648-94EB-4504-8DE0-00CE84FE1F50Q58765630-C508BADD-A30F-4BB2-BEAF-F60473CFF424
P2860
Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Persistence and adherence with ...... er: Early experience in Canada
@ast
Persistence and adherence with ...... er: Early experience in Canada
@en
type
label
Persistence and adherence with ...... er: Early experience in Canada
@ast
Persistence and adherence with ...... er: Early experience in Canada
@en
prefLabel
Persistence and adherence with ...... er: Early experience in Canada
@ast
Persistence and adherence with ...... er: Early experience in Canada
@en
P2093
P2860
P356
P1476
Persistence and adherence with ...... er: Early experience in Canada
@en
P2093
Adrian Wagg
Barbara Ramos
Billy Franks
Todd Berner
P2860
P304
P356
10.5489/CUAJ.3098
P577
2015-09-01T00:00:00Z